iQure

iQure Pharma Focuses on Developing Therapies for Neuropathic Pain, Epilepsy, and a Broader Range of Neurodegenerative Diseases. The Company Aims to Advance the Preclinical Development of Novel Therapeutic Compounds iQ-007 and iQ-008. iQ-007 Showed Positive Results in NIH ETSP Testing, Indicating the Compound’s Potential to Treat Pain, Epilepsy, and Possibly Neurodegenerative Diseases. iQ-008, a Novel Analgesic Compound, Is Progressing to the Next Phase of the Preclinical Screening Platform for Pain (PSPP), Established Under the HEAL Initiative to Promote the Identification of Potential Non-Addictive Treatments for Acute and Chronic Pain Conditions as Alternatives to Opioid Painkillers.